

Supplementary Material

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma


Jinpeng Li¹, Mingxin Kong², Guangji Yu³, Song Wang⁴, Zhaozhang Shi⁵, Huihui Han⁶, Yanyan Lin⁶, Jutian Shi¹, Jinlong Song¹

* **Correspondence:** Jinlong Song: jls7286@163.com

Supplementary table 1. Influence of joint timing on PFS

	mPFS (95% CI)	HR (95% CI)	P-value
Early combination	7.2 (3.0-11.4)	0.285 (0.124-0.655)	0.003
Late combination	11.7 (9.9-13.5)		

Early combination: treatment with camrelizumab and TKI prior to the first TACE treatment. Late combination: treatment with camrelizumab and TKI after the first TACE treatment. PFS: progression-free survival



Supplementary figure 1. Overall survival in the all patients by the Kaplan-Meier method per RECIST v1.1